Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
“Meryl Zausner is a highly accomplished financial and strategic leader, and I am delighted to welcome her to the Seres Board,” said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres. “Meryl’s extensive biopharmaceutical and oncology expertise will be an important asset to Seres as we continue to advance our extensive pipeline of microbiome therapeutic candidates.”
Ms. Zausner commented: “I am eager to contribute to Seres’ progress as it advances the development of microbiome therapeutics, a promising new treatment modality with potential to address a wide range of serious diseases.”
About Seres Therapeutics
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including Ms. Zausner’s potential contribution to the Company.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding; our limited operating
history; our unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development; our
reliance on third parties and collaborators to conduct our clinical
trials, manufacture our product candidates, and develop and
commercialize our product candidates, if approved; our lack of
experience in manufacturing, selling, marketing, and distributing our
product candidates; failure to compete successfully against other drug
companies; protection of our proprietary technology and the
confidentiality of our trade secrets; potential lawsuits for, or claims
of, infringement of third-party intellectual property or challenges to
the ownership of our intellectual property; our patents being found
invalid or unenforceable; our ability to retain key personnel and to
manage our growth; the potential volatility of our common stock; and our
management and principal stockholders have the ability to control or
significantly influence our business. These and other important factors
discussed under the caption “Risk Factors” in our Quarterly Report on
Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180904005085/en/
Source:
IR and PR Contact:
Seres
Therapeutics,
Carlo Tanzi, Ph.D., 617-203-3467
Vice President,
Investor Relations and Corporate Communications
ctanzi@serestherapeutics.com